GSK vs LINE · P/E 13, $103.31B cap vs rev $5.36B
GlaxoSmithKline PLC ADR (GSK) versus Lineage, Inc. Common Stock (LINE) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Lineage, Inc. Common Stock (LINE) is a reit - industrial company listed on NASDAQ.
GSK does not have a complete income-statement cache yet.
Latest reported LINE revenue for 2025-12-31 was $5.36B. Net income was -$100.0M. Revenue was up 0.3% from 2024-12-31 to 2025-12-31. LINE currently screens at market cap $10.41B.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. LINE currently screens at market cap $10.41B.
Not investment advice. Open the GSK and LINE stock pages for the full models.
Not investment advice.